Here’s Where to Get In – Oragenics (NYSEMKT:OG
Post# of 23058
Posted On: 06/15/2015 8:42:27 AM
Here’s Where to Get In – Oragenics (NYSEMKT:OGEN), Cleveland BioLabs (NASDAQ:CBLI), Amicus Therapeutics (NASDAQ:FOLD), Ibio (NYSEMKT:IBIO)
By Kurtis Sibley • June 15, 2015
Oragenics Inc (NYSEMKT:OGEN) gained +43.45% to close last trading session at $2.08. The company and Intrexon Corporation (XON), on June 10, 2015, jointly declared a new Exclusive Channel Collaboration (ECC) to pursue development of biotherapeutics for oral mucositis (OM) and other diseases and conditions of the oral cavity, throat, and esophagus, including clinical advancement of the ActoBiotic™ AG013 for the treatment of OM. OM results in the painful inflammation and ulceration of the membranes lining the oral cavity, throat, and esophagus and is among the most frequently reported adverse events associated with cancer therapy affecting up to 500,000 patients annually. At present there is no drug approved to prevent the condition broadly and therapies are primarily palliative, alleviating symptoms without addressing the underlying pathology, resulting in a significant unmet medical need.
Cleveland BioLabs, Inc. (NASDAQ:CBLI) rose +30.95% to end last trading session at $3.30. The company, on June 01, 2015, reported the release of results from a Phase 1 open-label, dose-escalation trial of entolimod in patients with advanced cancer at the 2015 annual meeting of the American Society of Clinical Oncology (ASCO), held from May 29 – June 2 in Chicago, Illinois. Entolimod is a specific, toll-like receptor 5 (TLR5) agonist that has shown preclinical potential in the immunotherapy of cancer. Entolimod administration activates innate and adaptive immune responses and mobilizes immunocytes to organs that have high TLR5 expression. These organs include liver and lung (common sites of metastases for many tumors) as well as bladder uroepithelium, which undergoes malignant transformation during the development of bladder cancers.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) advanced +7.90% to finish last trading session at $14.34. The company, on June 11, 2015, released the pricing of an underwritten offering of 16,981,132 shares of its common stock at $13.25 per share. The gross proceeds from the offering to Amicus are expected to be $225 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Amicus. In addition, Amicus has granted the underwriters a 30-day option to purchase up to an additional 2,547,170 shares of its common stock. The offering is expected to close on June 17, 2015, subject to customary closing conditions.
Ibio Inc (NYSEMKT:IBIO) added +7.53% to complete last trading session at $1.00. The company, on June 08, 2015, released three presentations focused on its products and technology at the Sixth International Conference on Plant-Based Vaccines, Antibodies & Biologics. Extending Platform Utility – iBio’s president, Robert Erwin, addressed the Plenary Session on June 8 and described how iBio has used its iBioLaunch platform together with the GRAMMR® technology of Novici Biotech, iBio’s contract partner, to enable the development of products that would otherwise be biologically or economically infeasible by overcoming yield limitations, increasing formulation flexibility, and increasing product value. Mr. Erwin provided examples of recent successes with antibodies and other therapeutic proteins relevant to iBio’s commercial strategy.
By Kurtis Sibley • June 15, 2015
Oragenics Inc (NYSEMKT:OGEN) gained +43.45% to close last trading session at $2.08. The company and Intrexon Corporation (XON), on June 10, 2015, jointly declared a new Exclusive Channel Collaboration (ECC) to pursue development of biotherapeutics for oral mucositis (OM) and other diseases and conditions of the oral cavity, throat, and esophagus, including clinical advancement of the ActoBiotic™ AG013 for the treatment of OM. OM results in the painful inflammation and ulceration of the membranes lining the oral cavity, throat, and esophagus and is among the most frequently reported adverse events associated with cancer therapy affecting up to 500,000 patients annually. At present there is no drug approved to prevent the condition broadly and therapies are primarily palliative, alleviating symptoms without addressing the underlying pathology, resulting in a significant unmet medical need.
Cleveland BioLabs, Inc. (NASDAQ:CBLI) rose +30.95% to end last trading session at $3.30. The company, on June 01, 2015, reported the release of results from a Phase 1 open-label, dose-escalation trial of entolimod in patients with advanced cancer at the 2015 annual meeting of the American Society of Clinical Oncology (ASCO), held from May 29 – June 2 in Chicago, Illinois. Entolimod is a specific, toll-like receptor 5 (TLR5) agonist that has shown preclinical potential in the immunotherapy of cancer. Entolimod administration activates innate and adaptive immune responses and mobilizes immunocytes to organs that have high TLR5 expression. These organs include liver and lung (common sites of metastases for many tumors) as well as bladder uroepithelium, which undergoes malignant transformation during the development of bladder cancers.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) advanced +7.90% to finish last trading session at $14.34. The company, on June 11, 2015, released the pricing of an underwritten offering of 16,981,132 shares of its common stock at $13.25 per share. The gross proceeds from the offering to Amicus are expected to be $225 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Amicus. In addition, Amicus has granted the underwriters a 30-day option to purchase up to an additional 2,547,170 shares of its common stock. The offering is expected to close on June 17, 2015, subject to customary closing conditions.
Ibio Inc (NYSEMKT:IBIO) added +7.53% to complete last trading session at $1.00. The company, on June 08, 2015, released three presentations focused on its products and technology at the Sixth International Conference on Plant-Based Vaccines, Antibodies & Biologics. Extending Platform Utility – iBio’s president, Robert Erwin, addressed the Plenary Session on June 8 and described how iBio has used its iBioLaunch platform together with the GRAMMR® technology of Novici Biotech, iBio’s contract partner, to enable the development of products that would otherwise be biologically or economically infeasible by overcoming yield limitations, increasing formulation flexibility, and increasing product value. Mr. Erwin provided examples of recent successes with antibodies and other therapeutic proteins relevant to iBio’s commercial strategy.
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'